Evidence Basis
This local Codex synthesis uses the generated Orphanet structured record for ORPHA:2704 and the PubMed caches integrated into the YAML. Falcon and OpenAI provider attempts both timed out without artifacts, so the curated YAML is based on local review of the deterministic evidence caches listed below.
Core Disease Mechanism
- Ochoa syndrome maps directly to MONDO:0000463 through ORPHA:2704, which uses the Orphanet preferred name Urofacial syndrome and lists Ochoa syndrome as a synonym.
- Orphanet records autosomal recessive inheritance and lists HPSE2 and LRIG2 as disease-causing genes.
- HPSE2 encodes inactive heparanase-2 and LRIG2 encodes leucine-rich repeats and immunoglobulin-like domains 2; both proteins have evidence of expression or localization in developing urinary-bladder nerves.
- Discovery studies identify HPSE2 and LRIG2 pathogenic variants in affected families, while GeneReviews summarizes biallelic variants in either gene as a route to molecular diagnosis.
- Mouse and human-development studies support a peripheral neurodevelopmental model: Lrig2 or Hpse2 mutant bladders have abnormal nerve density, reduced outflow-tract nitrergic innervation, and dysfunctional voiding.
Clinical Interpretation
- The syndrome is defined clinically by urinary bladder voiding dysfunction and abnormal facial movement with expression. The YAML maps the abnormal co-contraction component to HP:0034979 Facial synkinesis while retaining the clinical preferred term for the inverted smile/grimace phenotype.
- Functional bladder outlet obstruction can present prenatally as megacystis and postnatally produces poor stream, residual urine, dribbling incontinence, and recurrent urinary tract infection risk.
- Urinary stasis and high-pressure dysfunction lead to vesicoureteral reflux, hydronephrosis, renal insufficiency, and in severe cases progressive kidney failure.
- Constipation and encopresis are part of the bowel-dysfunction spectrum, and nocturnal lagophthalmos has also been documented.
- Orphanet frequency annotations provide structured support for the HPO-coded phenotype set, including recurrent urinary tract infections, urinary incontinence, vesicoureteral reflux, hydronephrosis, urethral obstruction, constipation, bowel incontinence, cryptorchidism, renal insufficiency, hypertension, and polydipsia.
Treatment-Relevant Mechanism
- Management is supportive and directed at preserving bladder emptying, preventing infection, and protecting kidney function.
- GeneReviews supports anticholinergic and alpha-1 adrenergic blocking medications to reduce bladder pressure and improve voiding.
- Catheterization or vesicostomy can improve bladder drainage when medication is insufficient.
- Acute urinary tract infections require rapid antibiotic therapy.
- Severe kidney failure may require dialysis or kidney transplantation.
YAML Integration Notes
- The pathophysiology graph is intentionally compact: biallelic HPSE2/LRIG2 dysfunction, aberrant bladder autonomic innervation, functional bladder outlet obstruction with incomplete emptying, urinary stasis/reflux/renal injury, and the hallmark abnormal facial movement outcome.
- Phenotypes are anchored primarily to ORPHA:2704 frequency annotations and reinforced by GeneReviews or mechanistic literature where useful.
- Genetics represent both causal genes separately, while the disease-level mechanism is modeled as a shared peripheral-neurodevelopmental pathway.